{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T06:53:27Z","timestamp":1777100007314,"version":"3.51.4"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>We report on an adrenocortical carcinoma (ACC) patient, which has exhausted previous treatment options and was scheduled for prostate-specific membrane antigen (PSMA)- and C-X-C motif chemokine receptor 4 (CXCR4)-targeted PET\/CT. We identified PSMA-avid pulmonary metastases exhibiting modest radiotracer accumulation, while chemokine receptor PET\/CT provided intense uptake. This dual-tracer molecular imaging approach revealed that chemokine receptor PET appears to be more suitable in patients with advanced ACC, indicating that CXCR4-directed radioligand therapy may be considered in such patients suffering from end-stage disease. Given its dismal prognosis, chemokine receptor-directed theranostics may therefore extend the therapeutic armamentarium as last-line option in advanced ACC.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005083","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T22:02:21Z","timestamp":1707861741000},"page":"369-370","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Exploring Theranostic Avenues in Adrenocortical Carcinoma Using Chemokine Receptor and Prostate-Specific Membrane Antigen\u2013Directed PET\/CT"],"prefix":"10.1097","volume":"49","author":[{"given":"Stefanie","family":"Hahner","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Diabetes, Department of Medicine I, University Hospital, University of W\u00fcrzburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian E.","family":"Serfling","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Samnick","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmina Teresa","family":"Fuss","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes, Department of Medicine I, University Hospital, University of W\u00fcrzburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britta","family":"Heinze","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes, Department of Medicine I, University Hospital, University of W\u00fcrzburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas K.","family":"Buck","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Schirbel","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes, Department of Medicine I, University Hospital, University of W\u00fcrzburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1097\/RLU.0000000000004202","article-title":"Imaging aldosterone-producing adrenocortical carcinoma with 68Ga-pentixafor PET\/CT","volume":"47","year":"2022","journal-title":"Clin Nucl Med"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"597878","DOI":"10.3389\/fendo.2020.597878","article-title":"Impact of the chemokine receptors CXCR4 and CXCR7 on clinical outcome in adrenocortical carcinoma","volume":"11","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.18632\/oncotarget.3217","article-title":"CXCR4 over-expression and survival in cancer: a system review and meta-analysis","volume":"6","year":"2015","journal-title":"Oncotarget"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1097\/RLU.0000000000001435","article-title":"Investigating the chemokine receptor 4 as potential theranostic target in adrenocortical cancer patients","volume":"42","year":"2017","journal-title":"Clin Nucl Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1210\/jc.2015-4021","article-title":"Prostate-specific membrane antigen is a potential antiangiogenic target in adrenocortical carcinoma","volume":"101","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2967\/jnumed.122.264207","article-title":"C-X-C motif chemokine receptor 4-targeted radioligand therapy in patients with advanced T-cell lymphoma","volume":"64","year":"2023","journal-title":"J Nucl Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"613248","DOI":"10.3389\/fendo.2021.613248","article-title":"Current status and future targeted therapy in adrenocortical cancer","volume":"12","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/RLU.0000000000004629","article-title":"Interobserver agreement rates on C-X-C motif chemokine receptor 4-directed molecular imaging and therapy","volume":"48","year":"2023","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:05:48Z","timestamp":1750532748000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005083","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,9]]}}}